Integumen lifted by wastewater test agreement

AIM-listed scientific analytics group Integumen (LON:SKIN) saw its share price rise by 8.33% to 1.95p (as of 15:40 BST) after signing a deal to develop and produce testing molecules for detecting COVID-19 in wastewater. A validation study will be carried out using a pilot batch before tests using the live virus within contained laboratories.

CEO Gerard Brandon commented: “Integumen’s business model is built on collaborating and cooperating with partners such as the Aptamer Group who have technologies that deliver solutions to major societal problems like COVID-19. Surveillance and testing of waterways for the presence of bacteria and viruses has recently gained recognition as an important step in identification of COVID-191. This collaboration is yet another example of the diagnostics industry working together to rapidly bring effective solutions in the fight against this global pandemic“.